Andrew Moshfeghi, MD, MBA: Treating neovascular AMD with anti-VEGF in real clinical settings

Pravin Dugel, EURETINA 2018 – Brolucizumab For Neovascular Age-related Macular DegenerationПодробнее

Brolucizumab for neovascular AMD: does it work? - Fast Papers #5Подробнее

Post-Approval Insights: Adverse Events of AMD Treatments – Pegcetacoplan, Faricimab, & BrolucizumabПодробнее

Charles Wykoff, MD, PhdПодробнее

Wet AMD 1 Anti VEGF protocols SOUKA Part 1 iCare AcademyПодробнее

A Call to Action: Saving the Eyesight of Patients With DiabetesПодробнее

New Therapies for Neovascular AMD and DME: What Have We Learned?Подробнее

Logistics of Newborn Eye Screening with Andrew Moshfeghi, MD, MBAПодробнее

Illustration of Neovascular AMD process by NovartisПодробнее

Influence of Topical Ofloxacin Following Intravitreal Anti-VEGF Injections on Endophthalmitis RatesПодробнее

Hemal Mehta, EURETINA 2018 – Wet Age-related Macular Degeneration and the PanOptica Eye DropПодробнее

PanOptica - OIS@AAO 2015Подробнее

Lecture: The Therapeutic Pipeline for Age-Related Macular Degeneration and Diabetic Macular EdemaПодробнее

Paul Mitchell, AAO 2018 – Age-related macular degeneration and the ARIES studyПодробнее

RWC 2021-E-Live CME on Neovascular AMD Sun,Apr 25, 2021 at 19:30 pm (IST)Подробнее

Wet AMD: Understanding the Role of Anti-VEGF TherapyПодробнее

Medicine in Our BackyardПодробнее

Wet AMD 2 Anti VEGF protocols SOUKA Part 2 iCare AcademyПодробнее

Hossein Ameri, MD, PhDПодробнее